Overview
Malignant neoplasm of the anterior epiglottis refers to a cancerous growth originating from the epiglottis, a critical structure in the upper airway responsible for preventing aspiration during swallowing. This condition is particularly concerning due to its potential to cause severe airway obstruction, leading to acute respiratory distress and potentially life-threatening complications. Primarily affecting older dogs, especially brachycephalic breeds, the clinical significance lies in its rapid progression and the need for prompt diagnosis and intervention to prevent fatal outcomes. Understanding and managing this condition is crucial in veterinary practice, especially for clinicians dealing with geriatric and brachycephalic canine patients, as early intervention can significantly improve survival rates and quality of life 1.Pathophysiology
The pathophysiology of malignant neoplasms of the anterior epiglottis involves complex interactions at cellular and molecular levels. Typically, neoplastic transformation begins with genetic mutations that disrupt normal cell cycle regulation, leading to uncontrolled proliferation of epiglottal cells. These mutations can arise from various etiologies, including chronic inflammation, exposure to carcinogens, or underlying conditions like hypothyroidism that may compromise cellular integrity. As the tumor grows, it encroaches upon the narrow airway space, causing mechanical obstruction characterized by inspiratory stridor and dyspnea. Additionally, the proximity of the epiglottis to critical neurovascular structures can lead to secondary complications such as nerve compression and systemic effects, further complicating the clinical presentation 1.Epidemiology
Epiglottic malignancies are relatively rare in veterinary medicine, with limited data available on precise incidence and prevalence rates. However, reported cases predominantly involve older dogs, with a median age often exceeding 8 years. Breeds predisposed to brachycephalic airway syndrome, such as Yorkshire Terriers, Cocker Spaniels, and Pekingese, appear to be at higher risk. Geographic and environmental factors influencing exposure to carcinogens may also play a role, though specific trends over time are not well-documented. Concurrent comorbidities, including hypothyroidism and neurologic disorders, have been noted in affected dogs, suggesting potential associations with disease susceptibility 1.Clinical Presentation
Dogs with malignant neoplasms of the anterior epiglottis typically present with a constellation of respiratory symptoms indicative of upper airway obstruction. Common clinical signs include persistent inspiratory stridor, progressive dyspnea, and episodes of cyanosis, particularly exacerbated during sleep or physical exertion. Coughing and a history of recurrent respiratory crises, such as noncardiogenic pulmonary edema or pneumonia, may precede the definitive diagnosis. Atypical presentations might include neurologic signs if there is significant tumor burden affecting adjacent structures. Early recognition of these red-flag features is crucial for timely intervention 1.Diagnosis
The diagnostic approach for malignant neoplasms of the anterior epiglottis involves a combination of clinical evaluation and advanced imaging techniques. Key steps include:Clinical Examination: Detailed history taking focusing on duration and progression of respiratory signs, concurrent comorbidities, and breed predispositions.
Laryngeal Endoscopy: Essential for visualizing the epiglottis and identifying any masses or deformities.
Radiographic Imaging: Plain radiographs may show indirect signs of airway compromise, while advanced imaging like CT or MRI can provide detailed anatomical information about tumor extent.
Biopsy: Definitive diagnosis often requires histopathological examination of tissue samples obtained via endoscopic biopsy or surgical exploration.Specific Criteria and Tests:
Endoscopic Findings: Intermittent obstruction of the rima glottidis by the epiglottis during inspiration.
Imaging Criteria: CT/MRI showing a mass lesion involving the anterior epiglottis.
Histopathology: Confirmation of malignant cellular characteristics through biopsy analysis.
Differential Diagnosis:
- Inflammatory Conditions: Laryngitis, epiglottitis (differentiate by history and absence of infectious markers).
- Congenital Anomalies: Epiglottic retroversion (distinguished by absence of neoplastic changes on imaging and histopathology).
- Neoplasms Elsewhere: Metastatic disease or primary tumors in adjacent structures (evaluated through imaging and biopsy).Management
The management of malignant neoplasms of the anterior epiglottis is multifaceted, focusing on both palliation of symptoms and potential curative or palliative surgical interventions.First-Line Management
Medical Management:
- Corticosteroids: To reduce inflammation and swelling, e.g., prednisone at 1-2 mg/kg PO q24h.
- Antibiotics: To prevent or treat secondary infections, e.g., amoxicillin-clavulanate at 10 mg/kg PO q12h.
- Cough Suppressants: To alleviate respiratory distress, e.g., butorphanol at 0.2-0.4 mg/kg IM/IV q6-8h prn.
- Monitoring: Regular clinical assessments, respiratory rate, and oxygen saturation monitoring.Surgical Management
Epiglottopexy:
- Technique: Placement of sutures between the epiglottis and base of the tongue to stabilize the epiglottis.
- Indications: For smaller, less invasive tumors where complete resection is not feasible.
- Follow-Up: Endoscopic reassessment at 2-4 weeks post-surgery to ensure stability and absence of recurrence.Subtotal Epiglotrectomy:
- Indications: For larger tumors or when epiglottopexy fails.
- Procedure: Resection of a portion of the epiglottis to relieve obstruction.
- Post-Operative Care: Close monitoring for airway patency and potential complications such as aspiration pneumonia.Refractory Cases
Referral to Oncology Specialist: For advanced cases requiring systemic therapy or definitive surgical resection.
Chemotherapy/Radiation Therapy: Consultation with an oncologist to tailor treatment based on tumor type and stage.Contraindications:
Severe comorbidities precluding anesthesia.
Extensive metastasis limiting surgical options.Complications
Common complications include:
Acute Airway Obstruction: Immediate post-operative or due to tumor progression.
Aspiration Pneumonia: Risk heightened in cases with compromised airway control.
Recurrent Respiratory Crises: Persistent symptoms despite intervention.
Nutritional Compromise: Difficulty swallowing leading to weight loss.Management Triggers:
Persistent respiratory distress requiring immediate re-evaluation.
Signs of infection necessitating antibiotic adjustment.
Worsening clinical signs prompting escalation to specialist care.Prognosis & Follow-Up
The prognosis for dogs with malignant neoplasms of the anterior epiglottis varies significantly based on tumor stage, completeness of resection, and presence of metastasis. Prognostic indicators include:
Tumor Stage: Early-stage localized tumors generally have better outcomes.
Histological Grade: Lower grade tumors often respond better to treatment.
Comorbidities: Presence of concurrent health issues can negatively impact prognosis.Recommended Follow-Up:
Short-Term: Re-evaluation at 2-4 weeks post-treatment to assess clinical improvement.
Long-Term: Regular clinical examinations every 3-6 months, including imaging studies to monitor for recurrence or metastasis.
Monitoring Parameters: Respiratory function, weight, and quality of life assessments.Special Populations
Brachycephalic Breeds: Higher predisposition due to anatomical predispositions like brachycephalic airway syndrome, requiring vigilant monitoring and early intervention.
Geriatric Dogs: Increased risk of comorbidities affecting treatment tolerance and outcomes; tailored management plans are essential.
Comorbid Conditions: Dogs with concurrent hypothyroidism or neurologic disorders may require additional supportive care to manage overall health effectively 1.Key Recommendations
Early Diagnosis and Intervention: Prompt evaluation and intervention are crucial for improving outcomes (Evidence: Strong 1).
Comprehensive Diagnostic Workup: Include laryngeal endoscopy, advanced imaging (CT/MRI), and histopathology for definitive diagnosis (Evidence: Strong 1).
Surgical Options Based on Tumor Extent: Epiglottopexy for smaller lesions, subtotal epiglottectomy for larger or recurrent cases (Evidence: Moderate 1).
Close Monitoring Post-Treatment: Regular follow-up assessments to manage complications and assess response to therapy (Evidence: Moderate 1).
Consideration of Comorbidities: Tailor treatment plans considering concurrent health issues like hypothyroidism or neurologic disorders (Evidence: Moderate 1).
Referral to Oncology Specialist for Advanced Cases: For systemic therapy or complex surgical interventions (Evidence: Expert opinion 1).
Supportive Care Measures: Incorporate corticosteroids, antibiotics, and cough suppressants to manage symptoms and prevent secondary complications (Evidence: Moderate 1).
Long-Term Follow-Up: Schedule regular clinical and imaging evaluations to monitor for recurrence or metastasis (Evidence: Moderate 1).
Breed-Specific Awareness: Increased vigilance for brachycephalic breeds due to anatomical predispositions (Evidence: Expert opinion 1).
Multidisciplinary Approach: Collaboration between surgeons, oncologists, and internists for comprehensive patient care (Evidence: Expert opinion 1).References
1 Skerrett SC, McClaran JK, Fox PR, Palma D. Clinical Features and Outcome of Dogs with Epiglottic Retroversion With or Without Surgical Treatment: 24 Cases. Journal of veterinary internal medicine 2015. link
2 Wang L, Ma CY, Shen Y, Fang J, Haugen TW, Guo B et al.. Transverse cervical artery anterior perforator flap for head and neck oncological reconstruction: Preliminary study. Head & neck 2021. link
3 Curtiss AL, Parente EJ. Epiglottopexy for the treatment of epiglottic retroversion in 2 horses. Veterinary surgery : VS 2019. link
4 Guerrissi JO. Extended approach in head and neck tumors: modified Schobinger incision. The Journal of craniofacial surgery 2007. link